BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 26, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the completion of its previously announced underwritten public offering of 8,214,286 shares of its common stock at a price to the public of $70.00 per share, including 1,071,428 shares sold

BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 23, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics .

BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 23, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Seattle Genetics .

-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 16, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ,

BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 2, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and

-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 12, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of

-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 10, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration ( FDA ) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug

Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lymphoma Analyses Describe ADCETRIS Activity in T-Cell and B-Cell Non-Hodgkin Lymphomas Across All Levels of CD30

- First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO